Osteopontin but not parathyroid hormone-related protein predicts prognosis in human renal cell carcinoma

Acta Oncologica

Volumn 52, Issue 1, 2013, Pages 159-165

  Papworth, Karin ^a   Bergh, Anders ^a   Grankvist, Kjell ^a   Ljungberg, Börje ^a   Sandlund, Johanna ^b   Rasmuson, Torgny ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; MEDROXYPROGESTERONE; OSTEOPONTIN; PARATHYROID HORMONE RELATED PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; CALCIUM; CD31 ANTIGEN;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; ADULT; CALCIUM BLOOD LEVEL; CANCER SPECIFIC SURVIVAL; COHORT ANALYSIS; CORRELATION ANALYSIS; FOLLOW UP; GROUPS BY AGE; HYPERCALCEMIA; MIDDLE AGED;

ANTIGENS, CD31; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OSTEOPONTIN; PARATHYROID HORMONE-RELATED PROTEIN; PROGNOSIS;

EID: 84871431194     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.693623     Document Type: Article

References (40)

1. Fedarko NS, Jain A, Karadag A, Fisher LW. Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specifi c matrix metalloproteinases. FASEB J 2004;18:734 - 6.
2. Brown LF, Berse B, Van de Water L, Papadopoulos- Sergiou A, Perruzzi CA, Manseau EJ, et al. Expression and distribution of osteopontin in human tissues: Widespread association with luminal epithelial surfaces. Mol Biol Cell 1992;3:1169 - 80. (Pubitemid 23088966)
3. Denhardt DT, Noda M. Osteopontin expression and function: Role in bone remodeling. J Cell Biochem Suppl 1998;30 - 31:92 - 102. (Pubitemid 29028730)
4. Denhardt DT, Guo X. Osteopontin: A protein with diverse functions. FASEB J 1993;7:1475 - 82. (Pubitemid 24003267)
5. Zhu Y, Denhardt DT, Cao H, Sutphin PD, Koong AC, Giaccia AJ, et al. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 2005;24:6555 - 63. (Pubitemid 41486638)
6. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, et al. Identifi cation of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003;9:59 - 67. (Pubitemid 36109716)
7. Oates AJ, Barraclough R, Rudland PS. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 1997;17:1 - 15. (Pubitemid 27525063)
8. Tuck AB, Chambers AF, Allan AL. Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management. J Cell Biochem 2007; 102:859 - 68. (Pubitemid 350036926)
9. Zhang DT, Yuan J, Yang L, Guo XN, Hao ZM, Han ZY, et al. Osteopontin expression and its relation to invasion and metastases in gastric cancer]. Zhonghua Zhong Liu Za Zhi 2005;27:167 - 9.
10. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer 1996;15:311 - 23. (Pubitemid 26399511)
11. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, et al. Osteopontin identifi ed as lead marker of colon cancer progression, using pooled sample expression profi ling. J Natl Cancer Inst 2002;94:513 - 21. (Pubitemid 34411290)
12. Matusan K, Dordevic G, Stipic D, Mozetic V, Lucin K. Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma. J Surg Oncol 2006;94:325 - 31. (Pubitemid 44330856)
13. Matusan K, Dordevic G, Mozetic V, Lucin K. Expression of osteopontin and CD44 molecule in papillary renal cell tumors. Pathol Oncol Res 2005;11:108 - 13. (Pubitemid 41039448)
14. Ramankulov A, Lein M, Kristiansen G, Meyer HA, Loening SA, Jung K. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol 2007;133:643 - 52. (Pubitemid 47077056)
15. Strewler GJ. The physiology of parathyroid hormone-related protein. N Engl J Med 2000;342:177 - 85. (Pubitemid 30051650)
16. Danks JA, Ebeling PR, Hayman J, Chou ST, Moseley JM, Dunlop J, et al. Parathyroid hormone-related protein: Immunohistochemical localization in cancers and in normal skin. J Bone Miner Res 1989;4:273 - 8. (Pubitemid 19121804)
17. Tsuchihashi T, Yamaguchi K, Miyake Y, Otsubo K, Nagasaki K, Honda S, et al. Parathyroid hormone-related protein in tumor tissues obtained from patients with humoral hypercalcemia of malignancy. J Natl Cancer Inst 1990;82:40 - 4. (Pubitemid 20020891)
18. Honda S, Yamaguchi K, Suzuki M, Sato Y, Adachi I, Kimura S, et al. Expression of parathyroid hormone-related protein mRNA in tumors obtained from patients with humoral hypercalcemia of malignancy. Jpn J Cancer Res 1988;79:677 - 81.
19. Burtis WJ, Brady TG, Orloff JJ, Ersbak JB, Warrell RP, Jr., Olson BR, et al. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 1990;322: 1106 - 12. (Pubitemid 20149527)
20. Grill V, Rankin W, Martin TJ. Parathyroid hormone-related protein (PTHrP) and hypercalcaemia. Eur J Cancer 1998; 34:222 - 9. (Pubitemid 28189190)
21. M assfelder T, Lang H, Schordan E, Lindner V, Rothhut S, Welsch S, et al. Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von Hippel-Lindau tumor suppressor gene. Cancer Res 2004;64:180 - 8. (Pubitemid 38114096)
22. Gotoh A, Kitazawa S, Mizuno Y, Takenaka A, Arakawa S, Matsumoto O, et al. Common expression of parathyroid hormone-related protein and no correlation of calcium level in renal cell carcinomas. Cancer 1993;71:2803 - 6. (Pubitemid 23120058)
23. Iwamura M, Wu W, Muramoto M, Ohori M, Egawa S, Uchida T, et al. Parathyroid hormone-related protein is an independent prognostic factor for renal cell carcinoma. Cancer 1999;86:1028 - 34. (Pubitemid 29439858)
24. Papworth K, Grankvist K, Ljungberg B, Rasmuson T. Parathyroid hormone-related protein and serum calcium in patients with renal cell carcinoma. Tumour Biol 2005; 26:201 - 6. (Pubitemid 41379746)
25. Yasui T, Fujita K, Sasaki S, Iguchi M, Hirota S, Nomura S, et al. Alendronate inhibits osteopontin expression enhanced by parathyroid hormone-related peptide (PTHrP) in the rat kidney. Urol Res 1998;26:355 - 60. (Pubitemid 28508973)
26. Allan A, Tuck A, Bramwell V, Vandenberg T, Winquist E, Chambers A. Contribution of osteopontin to the development of bone metastasis. Bone Metastasis 2005:107 - 23.
27. Liao J, McCauley LK. Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev 2006;25:559 - 71. (Pubitemid 46074999)
28. Ono N, Nakashima K, Rittling SR, Schipani E, Hayata T, Soma K, et al. Osteopontin negatively regulates parathyroid hormone receptor signaling in osteoblasts. J Biol Chem 2008;283:19400 - 9.
29. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classifi cation of renal cell tumours. J Pathol 1997;183:131 - 3.
30. Sobin L WC, International Union Against Cancer (UICC), editor. TNM classifi cation of malignant tumours, 6th ed. Hoboken, NJ: John Wiley & Sons; 2002.
31. Fuhrman SA, Lasky LC, Limas C. Prognostic signifi cance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655 - 63. (Pubitemid 13234762)
32. E mly JF, Gregory J, Bowden SJ, Ahmed A, Whittle MJ, Rushton DI, et al. Immunohistochemical localization of parathyroid hormone-related protein (PTHrP) in human term placenta and membranes. Placenta 1994;15:653 - 60. (Pubitemid 24295071)
33. Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljungberg B, Rasmuson T. Evaluation of CD31 (PECAM-1) expression using tissue microarray in patients with renal cell carcinoma. Tumour Biol 2007;28:158 - 64. (Pubitemid 46976002)
34. Budayr AA, Nissenson RA, Klein RF, Pun KK, Clark OH, Diep D, et al. Increased serum levels of a parathyroid hormone- like protein in malignancy-associated hypercalcemia. Ann Intern Med 1989;111:807 - 12. (Pubitemid 19283917)
35. Wai PY, Kuo PC. Osteopontin: Regulation in tumor metastasis. Cancer Metastasis Rev 2008;27:103 - 18.
36. Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 2007;67:330 - 40.
37. Le QT, Denko NC, Giaccia AJ. Hypoxic gene expression and metastasis. Cancer Metastasis Rev 2004;23:293 - 310. (Pubitemid 38881813)
38. Delahunt B, Bethwaite PB, Thornton A. Prognostic signifi - cance of microscopic ascularity for clear cell renal cell carcinoma. Br J Urol 1997;80:401 - 4. (Pubitemid 28312844)
39. Hiraki A, Ueoka H, Bessho A, Segawa Y, Takigawa N, Kiura K, et al. Parathyroid hormone-related protein measured at the time of fi rst visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia. Cancer 2002;95:1706 - 13.
40. Henderson M, Danks J, Moseley J, Slavin J, Harris T, McKinlay M, et al. Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases. J Natl Cancer Inst 2001;93:234 - 7. (Pubitemid 32166495)